Abstract
The current standard of care for the treatment of anal cancer as demonstrated by all of the completed phase 3 clinical trials remains 5-FU and mitomycin C in combination with radiation therapy. The basic elements of the approach outlined by Nigro have not changed in the last 30 years. Future phase 3 trials will serve to further perfect this approach and outline the role of HPV and dysplasia in the development and progression of this disease.
Original language | English (US) |
---|---|
Pages (from-to) | 389-394 |
Number of pages | 6 |
Journal | Surgical Oncology Clinics of North America |
Volume | 13 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2004 |
Externally published | Yes |
ASJC Scopus subject areas
- Surgery
- Oncology